Recording intelligenceAI-generated brief · check the source for context

Facial Implants - Part 1

1:01:52 recording · EN · 5 speakers

Listen to the original

Listen to the episode
Executive Summary AI
  • Host Leelangi Yedere-Wikrama convenes four ocular oncology specialists — Dr. Howard Kaufman, Dr. Bidas Meili, Dr. Hakan Demirci and Dr. Natalie Wolkoff — to cover periocular oncology from diagnosis through long-term surveillance.1:48
  • The panel calls targeted and immune-directed therapy from about 2011 to 2012 the decade's biggest change, alongside eye-sparing radiation and topical drugs, with patients now keeping eyes they would once have lost.3:39
  • Dr. Natalie Wolkoff's biopsy rules: build a differential before cutting, take photos, take enough tissue, avoid cautery and crush artifact, and excise deeper when melanoma is suspected because tumor thickness drives sentinel node decisions; Dr. Hakan Demirci adds biopsying at the lesion margin rather than an ulcerated, necrotic center.5:43
  • Drug therapy is reserved for locally advanced disease — by AJCC, T4 greater than 30 millimeters and invading the orbit — cases otherwise facing exenteration, and stage three melanoma with nodal metastasis, since surgery already cures most periocular cancers.17:18
  • For perineural spread Dr. Hakan Demirci's Michigan group treats one year and reports about 85% survival at two years and 75% at three, against radiation at 66 grays that relieved pain but left patients blind; Dr. Howard Kaufman adds a median time to response near 1.9 months in cutaneous squamous cell and doubled Merkel cell survival over the decade.31:48

Brief overview

Targeted and immune therapies now spare eyes and orbits in periocular cancer, making multidisciplinary care the standard.

  1. Send the tissue, and send enough of itNon-diagnostic superficial biopsies frustrate everyone; recurrent chalazia have come back as sebaceous carcinoma, so photograph the lesion, avoid cautery, and biopsy at the margin.
  2. Immunotherapy spares radiation and exenteration in perineural spreadWhere high-dose radiation to the skull base once guaranteed blindness, PD-1 checkpoint inhibitors gave Michigan roughly 85% two-year survival with returning cranial nerve function.
  3. Rare ocular cancers need an ocular oncologist following themSebaceous carcinoma and conjunctival melanoma metastasize during follow-up half the time and are routinely misclassified by general medical oncologists.

Questions this recording answers

10 questions, each answered where it is said
When should medical oncology be involved for periocular basal cell or squamous cell cancer?

Mainly for locally advanced disease. The clearest indication is a patient who would otherwise need orbital exenteration, or AJCC T4 disease, greater than 30 millimeters and invading the orbit. Surgery cures most cases with good reconstruction, so drugs are not used for cancers that are surgically treatable. Stage three eyelid melanoma with nodal spread is another indication.

Answered around 16:39
How do you avoid a non-diagnostic eyelid biopsy?

Take enough tissue rather than a superficial sliver, avoid crushing the specimen, and do not biopsy with cautery; excise with scissors or a blade. If melanoma is suspected, excise a larger, deeper area rather than shaving, because tumor thickness may decide whether a sentinel lymph node biopsy is needed. Talk to your pathologist in advance if unsure.

Answered around 9:18
Where on a lesion should the biopsy be taken?

Avoid the ulcerated center of a basal cell carcinoma, where the pathologist may see only necrotic tissue. Biopsy the margin where normal and neoplastic tissue meet for a higher yield. Target the tissue for your differential: for basal cell include all epidermis and dermis; for sebaceous carcinoma go to the tarsus, where it originates.

Answered around 13:19
How quickly does cutaneous squamous cell carcinoma respond to immune checkpoint inhibitors?

The median time to response is about 1.9 months, so after two doses there is usually a clear picture. Patients are reassessed after the second dose so a surgical window is not missed. A paper in press found almost all benefit came within the first two doses, suggesting treatment duration will be reduced over the next few years.

Answered around 25:41
What outcomes are seen with immunotherapy for perineural spread?

At Michigan, patients are treated for one year and then followed. Pain from trigeminal involvement mostly resolves, and around four to six months later facial and extraocular nerve function starts to recover. Survival was around 85% at two years and about 75% at three years, whereas patients treated with radiation before immunotherapy often did not survive a year.

Answered around 30:49
How common are immune-related side effects from checkpoint inhibitors?

Many patients develop some form of inflammation, most commonly diarrhea and dermatitis, plus thyroid, adrenal and other autoimmune problems. Ocular complications such as visual loss or uveitis occur in about 1% or less, and fatal side effects in about 1%. Overall rates are about 25-30% for a single agent like PD-1, rising to 50% or more with combination therapy.

Answered around 33:41
How is periocular Merkel cell carcinoma managed today?

Surgically manageable tumors get wide excision combined with sentinel lymph node biopsy, an approach supported by NCCN guidelines. This replaced empiric radiation of regional lymph nodes. Depending on results, patients are followed or given adjuvant immunotherapy or external beam radiotherapy. Immunotherapy is increasingly used and Merkel cell survival has doubled over the last decade.

Answered around 37:00
Does giving immunotherapy before surgery improve outcomes?

Across the board, giving immunotherapy in the neoadjuvant setting shows about a 20% improvement in outcomes compared with giving it as definitive therapy. So with regional nodal disease, neoadjuvant therapy is increasingly considered up front, and surgeons in cutaneous disease are doing less surgery, relying on adjuvant immunotherapy or targeted therapy afterward.

Answered around 20:47
Why do sebaceous carcinoma and conjunctival melanoma need specialized surveillance?

Both are unfamiliar to most medical oncologists. In both, about 50% of metastases occur during follow-up. Sebaceous carcinoma has a nodal predilection, so blanket CT and brain MRI workups do little. Conjunctival melanoma, like skin melanoma, carries a brain metastasis risk and is not mucosal melanoma. Panelists order their own systemic workups, at least yearly.

Answered around 56:31
Should a Jones tube be placed after medial canthal cancer reconstruction?

One panelist calls it her least favorite practice. When canaliculi are gone, focus on lower eyelid position and attach it at the posterior lacrimal crest. Placing a Jones tube, sometimes even after radiation, in patients who lost medial canthal tissue and canaliculi causes horrible dry eyes because it drains away the remaining tears.

Answered around 54:01
Key Quote

“As pathologists, we really don't care if you're right or wrong, but the information that's on the sheet is really helpful.”

— Dr. Natalie Wolkoff, Facial Implants - Part 1, at 10:08
Key Quote

“So please send it to the pathology.”

— Dr. Hakan Demirci, Facial Implants - Part 1, at 12:57
Key Quote

“So, we definitely know that overall, the survival for Merkel cell patients has doubled over the last decade, largely due to the introduction of immunotherapy.”

— Dr. Howard Kaufman, Facial Implants - Part 1, at 39:15
Key Quote

“So I'm a cancer remover and reconstructor.”

— Dr. Bidas Meili, Facial Implants - Part 1, at 46:08

Cite this

“Facial Implants - Part 1.” https://podcasts.apple.com/us/podcast/facial-implants-part-1/id1647047560. Transcript summary by WhipScribe, https://whipscribe.com/transcript-pages/facial-implants-part-1.html.

Report this page
What is wrong with this page?